AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.54 USD
-0.16 (-2.08%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.55 +0.01 (0.13%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Balance Sheet
Fiscal Year End for AngioDynamics, Inc falls in the month of May.
All items in Millions except Per Share data.
5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 76 | 45 | 29 | 48 | 54 |
Receivables | 44 | 53 | 52 | 35 | 31 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 61 | 55 | 51 | 49 | 60 |
Other Current Assets | 13 | 11 | 11 | 9 | 7 |
Total Current Assets | 193 | 164 | 143 | 141 | 153 |
Net Property & Equipment | 36 | 44 | 45 | 37 | 28 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 77 | 270 | 353 | 370 | 398 |
Deposits & Other Assets | 11 | 54 | 11 | 13 | 15 |
Total Assets | 318 | 533 | 553 | 561 | 594 |
Liabilities & Shareholders Equity | 5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 38 | 40 | 28 | 20 | 19 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 41 | 27 | 35 | 35 | 29 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 17 | 11 | 3 | 3 |
Total Current Liabilities | 91 | 84 | 74 | 58 | 51 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 13 | 16 | 20 | 24 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 50 | 25 | 20 | 40 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16 | 8 | 13 | 24 | 24 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 112 | 154 | 128 | 122 | 139 |
Shareholders Equity | 5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 610 | 599 | 587 | 574 | 562 |
Retained Earnings | -395 | -211 | -158 | -132 | -100 |
Other Equity | -4 | -5 | 1 | 3 | -1 |
Treasury Stock | 6 | 6 | 6 | 6 | 6 |
Total Shareholder's Equity | 206 | 378 | 424 | 439 | 455 |
Total Liabilities & Shareholder's Equity | 318 | 533 | 553 | 561 | 594 |
Total Common Equity | 206 | 378 | 424 | 439 | 455 |
Shares Outstanding | 40.00 | 39.20 | 38.70 | 38.10 | 37.60 |
Book Value Per Share | 5.14 | 9.65 | 10.97 | 11.53 | 12.10 |
Fiscal Year End for AngioDynamics, Inc falls in the month of May.
All items in Millions except Per Share data.
8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 76 | 78 | 61 | 58 |
Receivables | NA | 44 | 49 | 52 | 50 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 61 | 58 | 64 | 60 |
Other Current Assets | NA | 13 | 11 | 9 | 8 |
Total Current Assets | NA | 193 | 197 | 185 | 175 |
Net Property & Equipment | NA | 36 | 37 | 43 | 43 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 77 | 82 | 263 | 266 |
Deposits & Other Assets | NA | 11 | 9 | 8 | 9 |
Total Assets | NA | 318 | 325 | 500 | 494 |
Liabilities & Shareholders Equity | 8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 38 | 35 | 38 | 25 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 41 | 31 | 29 | 26 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 12 | 20 | 11 | 7 |
Total Current Liabilities | NA | 91 | 86 | 78 | 57 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 6 | 18 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 14 | 3 | 7 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 112 | 106 | 98 | 66 |
Shareholders Equity | 8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 610 | 609 | 605 | 604 |
Retained Earnings | NA | -395 | -382 | -194 | -165 |
Other Equity | NA | -4 | -3 | -5 | -6 |
Treasury Stock | NA | 6 | 6 | 6 | 6 |
Total Shareholder's Equity | NA | 206 | 219 | 401 | 428 |
Total Liabilities & Shareholder's Equity | NA | 318 | 325 | 500 | 494 |
Total Common Equity | 0 | 206 | 219 | 401 | 428 |
Shares Outstanding | 40.20 | 40.00 | 39.80 | 39.80 | 39.80 |
Book Value Per Share | 0.00 | 5.14 | 5.49 | 10.08 | 10.75 |